Tumor necrosis factor alpha in mycobacterial infection

Seminars in Immunology

Volumn 26, Issue 3, 2014, Pages 203-209

  Dorhoi, Anca ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Cell death; Granuloma; Immunotherapy; Inflammation; Mycobacterium tuberculosis

Indexed keywords

CYTOKINE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

BIOGENESIS; CYTOKINE PRODUCTION; GRANULOMA; HUMAN; INFLAMMATION; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904042898     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.04.003     Document Type: Review

References (101)

1. WHO Global tuberculosis report 2013 2013, WHO Press, Geneva.
2. Ernst J.D. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012, 12(August (8)):581-591.
3. Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 2012, 12(May (5)):352-366.
4. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. III. Analysis of mechanism. J Exp Med 1968, 128(December (6)):1267-1279.
5. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. II. Correlation of the in vitro response with skin reactivity. J Exp Med 1968, 128(December (6)):1255-1265.
6. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon. J Exp Med 1968, 128(December (6)):1237-1254.
7. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975, 72(September (9)):3666-3670.
8. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994, 64(3):529-564.
9. Drolet G.J., Lowell A.M. A half century's progress against tuberculosis in New York city: 1900-1950 1952, New York Tuberculosis and Health Association, New York.
10. Kaufmann S.H., Winau F. From bacteriology to immunology: the dualism of specificity. Nat Immunol 2005, 6(November (11)):1063-1066.
11. Barnes P.F., Fong S.J., Brennan P.J., Twomey P.E., Mazumder A., Modlin R.L. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990, 145(July (1)):149-154.
12. Barnes P.F., Lu S., Abrams J.S., Wang E., Yamamura M., Modlin R.L. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993, 61(August (8)):3482-3489.
13. Casarini M., Ameglio F., Alemanno L., Zangrilli P., Mattia P., Paone G., et al. Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. Am J Respir Crit Care Med 1999, 159(January (1)):143-148.
14. Law K., Weiden M., Harkin T., Tchou-Wong K., Chi C., Rom W.N. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996, 153(February (2)):799-804.
15. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P. The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
16. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992, 10:411-452.
17. Rook G.A., Taverne J., Leveton C., Steele J. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987, 62(October (2)):229-234.
18. Valone S.E., Rich E.A., Wallis R.S., Ellner J.J. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun 1988, 56(December (12)):3313-3315.
19. Henderson R.A., Watkins S.C., Flynn J.L. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997, 159(July (2)):635-643.
20. Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35(December (6)):1023-1034.
21. Thurnher M., Ramoner R., Gastl G., Radmayr C., Bock G., Herold M., et al. Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int J Cancer 1997, 70(January (1)):128-134.
22. Fremond C.M., Yeremeev V., Nicolle D.M., Jacobs M., Quesniaux V.F., Ryffel B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J Clin Invest 2004, 114(December (12)):1790-1799.
23. Dorhoi A., Desel C., Yeremeev V., Pradl L., Brinkmann V., Mollenkopf H.J., et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med 2010, 207(April (4)):777-792.
24. Spencer C.T., Abate G., Sakala I.G., Xia M., Truscott S.M., Eickhoff C.S., et al. Granzyme A produced by gamma(9)delta(2) T cells induces human macrophages to inhibit growth of an intracellular pathogen. PLoS Pathog 2013, 9(January (1)):e1003119.
25. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148(February (3)):434-446.
26. Beltan E., Horgen L., Rastogi N. Secretion of cytokines by human macrophages upon infection by pathogenic and non-pathogenic mycobacteria. Microb Pathog 2000, 28(May (5)):313-318.
27. Yadav M., Roach S.K., Schorey J.S. Increased mitogen-activated protein kinase activity and TNF-alpha production associated with Mycobacterium smegmatis- but not Mycobacterium avium-infected macrophages requires prolonged stimulation of the calmodulin/calmodulin kinase and cyclic AMP/protein kinase A pathways. J Immunol 2004, 172(May (9)):5588-5597.
28. Rajaram M.V., Ni B., Morris J.D., Brooks M.N., Carlson T.K., Bakthavachalu B., et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci U S A 2011, 108(October (42)):17408-17413.
29. Faldt J., Dahlgren C., Ridell M. Difference in neutrophil cytokine production induced by pathogenic and non-pathogenic mycobacteria. APMIS 2002, 110(September (9)):593-600.
30. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010, 137(January (1)):122-128.
31. Harari A., Rozot V., Enders F.B., Perreau M., Stalder J.M., Nicod L.P., et al. Dominant TNF-alpha+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med 2011, 17(March (3)):372-376.
32. Arora P., Foster E.L., Porcelli S.A. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis. Adv Exp Med Biol 2013, 783:199-223.
33. Szalay G., Zugel U., Ladel C.H., Kaufmann S.H. Participation of group 2 CD1 molecules in the control of murine tuberculosis. Microbes Infect 1999, 1(December (14)):1153-1157.
34. Barnes P.F., Abrams J.S., Lu S., Sieling P.A., Rea T.H., Modlin R.L. Patterns of cytokine production by mycobacterium-reactive human T-cell clones. Infect Immun 1993, 61(January (1)):197-203.
35. Lang F., Peyrat M.A., Constant P., Davodeau F., David-Ameline J., Poquet Y., et al. Early activation of human V gamma 9 V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 1995, 154(June (11)):5986-5994.
36. Gold M.C., Cerri S., Smyk-Pearson S., Cansler M.E., Vogt T.M., Delepine J., et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 2010, 8(6):e1000407.
37. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2(June (6)):561-572.
38. Kindler V., Sappino A.P., Grau G.E., Piguet P.F., Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56(March (5)):731-740.
39. Chan J., Xing Y., Magliozzo R.S., Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175(April (4)):1111-1122.
40. Flesch I.E., Kaufmann S.H. Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. Infect Immun 1990, 58(August (8)):2675-2677.
41. Denis M. Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria. Clin Exp Immunol 1991, 83(March (3)):466-471.
42. Byrd T.F. Tumor necrosis factor alpha (TNFalpha) promotes growth of virulent Mycobacterium tuberculosis in human monocytes iron-mediated growth suppression is correlated with decreased release of TNFalpha from iron-treated infected monocytes. J Clin Invest 1997, 99(May (10)):2518-2529.
43. Engele M., Stossel E., Castiglione K., Schwerdtner N., Wagner M., Bolcskei P., et al. Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J Immunol 2002, 168(February (3)):1328-1337.
44. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162(March (6)):3504-3511.
45. Kaneko H., Yamada H., Mizuno S., Udagawa T., Kazumi Y., Sekikawa K., et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest 1999, 79(April (4)):379-386.
46. Egen J.G., Rothfuchs A.G., Feng C.G., Winter N., Sher A., Germain R.N. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 2008, 28(February (2)):271-284.
47. Senaldi G., Yin S., Shaklee C.L., Piguet P.F., Mak T.W., Ulich T.R. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996, 157(December (11)):5022-5026.
48. Roach D.R., Bean A.G., Demangel C., France M.P., Briscoe H., Britton W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168(May (9)):4620-4627.
49. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8(October (10)):601-611.
50. Lin P.L., Myers A., Smith L., Bigbee C., Bigbee M., Fuhrman C., et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010, 62(February (2)):340-350.
51. Botha T., Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003, 171(September (6)):3110-3118.
52. Bekker L.G., Moreira A.L., Bergtold A., Freeman S., Ryffel B., Kaplan G. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent. Infect Immun 2000, 68(December (12)):6954-6961.
53. Reece S.T., Loddenkemper C., Askew D.J., Zedler U., Schommer-Leitner S., Stein M., et al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest 2010, 120(September (9)):3365-3376.
54. Clay H., Volkman H.E., Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008, 29(August (2)):283-294.
55. Kundu M., Pathak S.K., Kumawat K., Basu S., Chatterjee G., Pathak S., et al. A TNF- and c-Cbl-dependent FLIP(S)-degradation pathway and its function in Mycobacterium tuberculosis-induced macrophage apoptosis. Nat Immunol 2009, 10(August (8)):918-926.
56. Keane J., Remold H.G., Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 2000, 164(February (4)):2016-2020.
57. Martin C.J., Booty M.G., Rosebrock T.R., Nunes-Alves C., Desjardins D.M., Keren I., et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 2012, 12(September (3)):289-300.
58. Davis J.M., Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009, 136(January (1)):37-49.
59. Balcewicz-Sablinska M.K., Keane J., Kornfeld H., Remold H.G. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998, 161(September (5)):2636-2641.
60. Divangahi M., Behar S.M., Remold H. Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis. Adv Exp Med Biol 2013, 783:103-120.
61. Keane J., Balcewicz-Sablinska M.K., Remold H.G., Chupp G.L., Meek B.B., Fenton M.J., et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997, 65(January (1)):298-304.
62. Declercq W., Vanden Berghe T., Vandenabeele P. RIP kinases at the crossroads of cell death and survival. Cell 2009, 138(July (2)):229-232.
63. Roca F.J., Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013, 153(April (3)):521-534.
64. Mootoo A., Stylianou E., Arias M.A., Reljic R. TNF-alpha in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets 2009, 8(March (1)):53-62.
65. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc Natl Acad Sci U S A 2001, 98(May (10)):5752-5757.
66. Kahler A.K., Persson A.S., Sanchez F., Kallstrom H., Apt A.S., Schurr E., et al. A new coding mutation in the Tnf-alpha leader sequence in tuberculosis-sensitive I/St mice causes higher secretion levels of soluble TNF-alpha. Genes Immun 2005, 6(October (7)):620-627.
67. Bekker L.G., Maartens G., Steyn L., Kaplan G. Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998, 178(August (2)):580-584.
68. Waitt C.J., Peter K.B., White S.A., Kampmann B., Kumwenda J., Heyderman R.S., et al. Early deaths during tuberculosis treatment are associated with depressed innate responses, bacterial infection, and tuberculosis progression. J Infect Dis 2011, 204(August (3)):358-362.
69. Fallahi-Sichani M., El-Kebir M., Marino S., Kirschner D.E., Linderman J.J. Multiscale computational modeling reveals a critical role for TNF-alpha receptor 1 dynamics in tuberculosis granuloma formation. J Immunol 2011, 186(March (6)):3472-3483.
70. Ray J.C., Flynn J.L., Kirschner D.E. Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J Immunol 2009, 182(March (6)):3706-3717.
71. Marino S., Myers A., Flynn J.L., Kirschner D.E. TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model. J Theor Biol 2010, 265(August (4)):586-598.
72. Cilfone N.A., Perry C.R., Kirschner D.E., Linderman J.J. Multi-scale modeling predicts a balance of tumor necrosis factor-alpha and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection. PLoS One 2013, 8(7):e68680.
73. Van Hauwermeiren F., Vandenbroucke R.E., Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 2011, 22(October (5-6)):311-319.
74. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345(October (15)):1098-1104.
75. Galloway J.B., Mercer L.K., Moseley A., Dixon W.G., Ustianowski A.P., Helbert M., et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013, 72(February (2)):229-234.
76. Xie X., Li F., Chen J.W., Wang J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: from bench to bedside. J Microbiol Immunol Infect 2013, (May). 10.1016/j.jmii.2013.03.005.
77. Plessner H.L., Lin P.L., Kohno T., Louie J.S., Kirschner D., Chan J., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007, 195(June (11)):1643-1650.
78. Bruns H., Meinken C., Schauenberg P., Harter G., Kern P., Modlin R.L., et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119(May (5)):1167-1177.
79. Barber D.L., Andrade B.B., Sereti I., Sher A. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none. Nat Rev Microbiol 2012, 10(February (2)):150-156.
80. Quesniaux V.F., Jacobs M., Allie N., Grivennikov S., Nedospasov S.A., Garcia I., et al. TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun 2010, 11:157-179.
81. Blackmore T.K., Manning L., Taylor W.J., Wallis R.S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 2008, 47(November (10)):e83-e85.
82. Paige C., Bishai W.R. Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol 2010, 12(March (3)):301-309.
83. Wallis R.S. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009, 22(August (4)):403-409.
84. Skerry C., Harper J., Klunk M., Bishai W.R., Jain S.K. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One 2012, 7(6):e39680.
85. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010, 10(September (9)):621-629.
86. Velayati A.A., Farnia P., Masjedi M.R. The totally drug resistant tuberculosis (TDR-TB). Int J Clin Exp Med 2013, 6(4):307-309.
87. Brines M., Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008, 264(November (5)):405-432.
88. Ebrahim O., Folb P.I., Robson S.C., Jacobs P. Blunted erythropoietin response to anaemia in tuberculosis. Eur J Haematol 1995, 55(October (4)):251-254.
89. Satoh M., Ueta H., Tokura T., Sasaki T., Kashihara N. Erythropoietin-producing tubercle granuloma in a hemodialysis patient. BMC Nephrol 2013, 14(April (1)):91.
90. Harder J., Meyer-Hoffert U., Teran L.M., Schwichtenberg L., Bartels J., Maune S., et al. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000, 22(June (6)):714-721.
91. Liu Y., Mei J., Gonzales L., Yang G., Dai N., Wang P., et al. IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol 2011, 186(March (5)):3197-3205.
92. Tramontana J.M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995, 1(May (4)):384-397.
93. Schoeman J.F., Springer P., van Rensburg A.J., Swanevelder S., Hanekom W.A., Haslett P.A., et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004, 19(April (4)):250-257.
94. Tsenova L., Mangaliso B., Muller G., Chen Y., Freedman V.H., Stirling D., et al. Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother 2002, 46(June (6)):1887-1895.
95. Kaufmann S.H. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol 2008, 9(July (7)):705-712.
96. Dannenberg A.M. Pathogenesis of human pulmonary tuberculosis 2006, ASM Press, Washington, DC.
97. Gengenbacher M., Kaufmann S.H. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012, 36(May (3)):514-532.
98. Pan H., Yan B.S., Rojas M., Shebzukhov Y.V., Zhou H., Kobzik L., et al. Ipr1 gene mediates innate immunity to tuberculosis. Nature 2005, 434(April (7034)):767-772.
99. Turner O.C., Basaraba R.J., Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infect Immun 2003, 71(February (2)):864-871.
100. Smith D.W., Harding G.E. Animal model of human disease. Pulmonary tuberculosis. Animal model: experimental airborne tuberculosis in the guinea pig. Am J Pathol 1977, 89(October (1)):273-276.
101. Swaim L.E., Connolly L.E., Volkman H.E., Humbert O., Born D.E., Ramakrishnan L. Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity. Infect Immun 2006, 74(November (11)):6108-6117.